| Name | Title | Contact Details |
|---|
BIOSAFE Inc is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BioPlus Specialty Pharmacy is a leading independent, national specialty pharmacy with 28 years of innovative excellence and the first and only specialty pharmacy to offer a two-hour turnaround from referral to patient acceptance. BioPlus earned a #1 patient satisfaction ranking in both oncology and hepatitis C in Zitter`s Specialty Pharmacy Patient Satisfaction Survey. Our RxExpress program moves each prescription through our system in the most streamline way. From the 2-Hour Patient Acceptance Guarantee at the beginning to the 2-Day Ready 2 Ship at the end, along with free overnight shipping, physicians and patients can trust BioPlus to provide effective service that`s delivered fast. By keeping the wait time for medications as short as possible, patients don`t have to wait to get back to living their lives. BioPlus provides a complete range of specialty services, including for cancer, hepatitis C, multiple sclerosis, rheumatoid arthritis, dermatology, and other complex, chronic conditions. We are a privately-held, pharmacist-owned company based in Altamonte Springs, Florida and accredited by URAC, VIPPS, and ACHC with a Distinction in Oncology.`
Unlocking the health benefits of cannabinoids. Learn More Unlocking the health benefits on cannabinoidsLearn more We are a team of medical experts. Meet our team https://sanitygroup.com/wp-content/uploads/2020/11/SP_Homepage_Video_Compressed_BW.mp4 Med...
Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. Nabriva was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna, Austria and commenced operations in February 2006. The new organization included small molecule assets, including pleuromutilin structure activity relationships (SAR) knowledge and was focused on synthesis of pleuromutilins for systemic human use. Following identification of our lead compound lefamulin and based on the clinical results of lefamulin for Acute Skin and Skin Structure Infections. We believed that targeted in vitro spectrum of activity for the common pathogens causing Community Acquired Bacterial Pneumonia (CABP), would allow us to develop lefamulin as the first pleuromutilin IV and oral antibiotic for human systemic administration for CABP. In 2014, we opened our US office in King of Prussia, Pennsylvania and completed an IPO on the NASDAQ under the ticker NBRV in September 2015. With net proceeds from our IPO, we initiated two global, registrational Phase 3 clinical trials of lefamulin for the treatment of moderate to severe CABP. Based on our estimates regarding patient enrollment, we expect to have top-line data available for both trials in the second half of 2017. If the results of these trials are favorable, including achievement of the primary efficacy endpoints of the trials, we expect to submit applications for marketing approval for lefamulin for the treatment of CABP in both the United States and Europe in 2018. As of April 1, 2016, Nabriva employed 52 employees at its headquarters in Vienna, Austria, and its office in King of Prussia, Pennsylvania, United States.
We are a substance abuse treatment program focusing primarily on opioid use disorders. We have locations in Cincinnati, Forest Park, Middletown, and Dayton. Services include individual and group counseling, urinalysis, case management, and cri...